The role of upfront autologous SCT for primary AL amyloidosis

Webinar Session: Wednesday, July 29th at 6 PM (ET) Zoom Meeting

(These sessions will not be recorded due to patient involvement and HIPAA laws)

To Register HERE

Join us for an informative session with Dr. Tibor Kovacsovics on the role of upfront autologous stem cell transplantation in treating primary AL amyloidosis. Learn how this treatment may affect outcomes, what patients can expect during the process, and how it fits into overall disease management. Helpful for patients and caregivers.

Dr. Tibor Kovacsovics is Chief of Hematology and Medical Director of Leukemia at City of Hope Cancer Center Phoenix. A hematologist-oncologist with 20 years of clinical research experience, he specialises in AML, ALL, stem cell transplantation, and amyloidosis. He trained at Harvard Medical School/MGH/Brigham and Women’s, co-founded the Utah Amyloidosis Program at Huntsman Cancer Institute, and has served as principal investigator on dozens of landmark hematology studies.